A5034038898- PI3K/AKT/mTOR signaling in cancer
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Screening and Detection
- Reproductive Biology and Fertility
- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Ovarian function and disorders
- Monoclonal and Polyclonal Antibodies Research
- Genomic variations and chromosomal abnormalities
- Lung Cancer Treatments and Mutations
- Prenatal Screening and Diagnostics
- Synthesis and biological activity
- Cytokine Signaling Pathways and Interactions
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Birth, Development, and Health
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Growth Hormone and Insulin-like Growth Factors
- Endometrial and Cervical Cancer Treatments
- Cardiac Ischemia and Reperfusion
Institute of Oncology Research
2005-2021
Ente Ospedaliero Cantonale
2017-2019
University of Insubria
1999-2006
Ospedale di Circolo e Fondazione Macchi
1998-2003
University of Bern
2001
University of Pavia
1992-1998
Summary Among B‐cell lymphomas mantle cell lymphoma (MCL) has the worst prognosis. By using a combination of genomic and expression profiling (Affymetrix GeneChip Mapping 10k Xba131 U133 set), we analysed 26 MCL samples to identify genes relevant pathogenesis that could represent new therapeutic targets. Recurrent deletions gains were detected. Genes identified as overexpressed in regions DNA gain on 3q, 6p, 8q, 9q, 16p 18q, including cancer BCL2 MYC . transcripts with high correlation...
Abstract Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition has shown activity patients. Here, we extensively characterized vitro vivo mechanism action PQR309 (bimiralisib), a novel oral selective dual inhibitor under clinical evaluation, preclinical models. Experimental Design: This study included screening on large panel cell lines, both as single agent combination, validation experiments models primary cells,...
Premature ovarian failure is defined as cessation of function under the age 40 years and affects approximately 1% women in general population. The aetiology this disorder still unknown most cases. Although there have been some reports familial premature failure, very little known about incidence inheritance pattern its idiopathic form. aims study were to investigate a homogeneous group patients with menopause identify possible clinical differences between sporadic form failure. A total 71...
Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds cells expressing specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, based on the anti-CD19 antibody linked via sulfo-SPDB DNA-alkylating agent DGN462. huB4-DGN462 had improved in vitro anti-proliferative and activity compared across multiple B-cell lymphoma human acute lymphoblastic leukemia cell lines. In...
Genetic factors may influence the timing of menopause. Premature ovarian failure (POF) has recently been identified as a genetic entity, but no data are available on early menopause (EM). We investigated 36 patients with EM (age between 40 and 45 years age) using cytogenetic pedigree analysis. In 30 this study was idiopathic 15 subjects (50%) had familial condition or POF. Pedigree analysis revealed dominant pattern inheritance through maternal paternal relatives. Our reveal that POF show...
Abstract Background To prospectively evaluate the role of procalcitonin (PCT) in screening patients with thyroid nodules for medullary carcinoma (MTC). Materials and methods We measured PCT 2705 referred to our centre between January 2011 December 2017. Those a positive were operated after confirmatory tests such as fine‐needle aspiration, measurement calcitonin (CT) serum aspiration washouts or CT stimulation testing. Patients negative based on results further diagnostics. The diagnostic...
Background We estimated the cost-effectiveness of universal DNA screening for Lynch syndrome (LS) among newly diagnosed patients with colorectal cancer (CRC) followed by cascade relatives from Swiss healthcare system perspective. Methods integrated decision trees Markov models to calculate incremental cost per quality-adjusted life-year saved all CRC (alternative strategy) compared tumour-based testing sequencing (current strategy). Results The alternative strategy has an ratio CHF65 058...
Background: Insulin-like growth factor I (IGF-I) and other markers of insulin resistance (IRm) might influence the penetrance BRCA gene mutation. In a demonstration project on mutation carriers we tested effect ‘Mediterranean diet’, with moderate protein restriction, serum levels IGF-I IRm. Methods: carriers, or without breast cancer, aged 18–70 years metastases were eligible. After baseline examinations, women randomized to an active dietary intervention control group. The group attended...
This study was conducted to assess if the delivery of a previous growth-retarded (IUGR) fetus increases risk having an IUGR in subsequent pregnancies and explore familial pattern transmission is involved.Seventy consecutive multiparous women whose (group 1) 70 controls 2) were enrolled this study.The proportion who developed preeclampsia (9 versus 2, p = 0.05) had delivered pregnancy (20 4, < higher group 1 than 2. There no difference incidence chronic hypertension, diabetes, smoking,...
The first pathogenetic step in multiple myeloma is the emergence of a limited number clonal plasma cells, clinically known as monoclonal gammopathy undetermined significance (MGUS). Patients with MGUS do not have symptoms or end-organ damage but they 1% annual risk progression to related malignant disorders. With myeloma, complex genetic events occur neoplastic cell. Karyotyping and fluorescence in-situ hybridization (FISH) were shown be prognostic value patients myeloma. Tc-sestamibi...
Aims and background Epidemiological investigations on the frequency of hereditary nonpolyposis colorectal cancer (HNPCC) syndrome are few have shown a variable worldwide incidence ranging from 1% to 7% all cancers (CRCs). In Italy, relevant differences been observed: 2.8-3% CRCs in northern regions less than southern regions. The aim present study was investigate HNPCC selected area Italy belonging Lombardy Cancer Registry. Methods design We analyzed 197 consecutive patients with newly...